Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single‐center cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single‐center cohort

Published:2019-07-26 Issue:11 Volume:66 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Barg Assaf A.¹²³^ORCID,Avishai Einat¹²³,Budnik Ivan⁴,Levy‐Mendelovich Sarina¹²³,Barazani Tami B.²³,Kenet Gili¹²³^ORCID,Livnat Tami¹²³

Affiliation:

1. Sackler Faculty of MedicineTel Aviv University Tel Aviv Israel

2. The Israeli National Hemophilia Center and Thrombosis UnitSheba Medical Center Tel Hashomer Israel

3. The Amalia Biron Research Institute of Thrombosis and HemostasisSheba Medical Center Tel Hashomer Israel

4. Department of PathophysiologySechenov First Moscow State Medical University (Sechenov University) Moscow Russia

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.27886

Reference28 articles.

1. Optimizing outcomes for patients with severe haemophilia A

2. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project

3. Toward optimal therapy for inhibitors in hemophilia

4. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy

5. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries;BMJ Open;2024-09

2. Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia;Blood Advances;2024-05-30

3. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

4. Unresolved hemostasis issues in haemophilia;Haemophilia;2024-04

5. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3